… ProQR nominates Bart Filius, COO and CFO at Galapagos and … and Bart to the Supervisory Board at a pivotal point in ProQR’s advancement to become a fully integrated inherited … retinal disease company,” said Daniel A. de Boer, CEO at ProQR. “Theresa brings significant global commercial and …
… ProQR annonce des premiers résultats positifs pour l'essai de … CAMBRIDGE, Massachussets, 11 oct. 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq :PRQR), une entreprise dédiée … héréditaires dans son ensemble », a déclaré Stephen R. Russell, M.D., professeur Schrage d'ophtalmologie et des …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
… ProQR traite le premier patient dans l’essai STELLAR de Phase … CAMBRIDGE, Massachusetts, 11 mars 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq : PRQR), société consacrée à … STELLAR examinera si le QR-421a (traitement par ARN de ProQR) peut ralentir la progression de la maladie, voire …
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
… ProQR to present QR-010 data at the European Cystic Fibrosis … QR-010 can treat all manifestations of CF,” said Noreen R. Henig, MD, Chief Medical Officer of ProQR. “I am very pleased that enrollment of the Phase 1b …